Abstract:Despite prophylactic vaccination campaigns, high-risk human papillomavirus (HPV)-induced cervical cancer remains a significant health threat among women, especially in developing countries. The initial occurrence and consequent progression of this cancer type primarily rely on, E6 and E7, two key viral oncogenes expressed constitutively, inducing carcinogenesis. Thus, E6/E7 have been proposed as ideal targets for HPV-related cancer diagnosis and treatment. In this study, three novel HPV16 E6-binding affibody molecules (ZHPV16E61115, ZHPV16E61171, and ZHPV16E61235) were isolated from a randomized phage display library and cloned for bacterial production. These affibody molecules showed high binding affinity and specificity for recombinant and native HPV16 E6 as determined by surface plasmon resonance, indirect immunofluorescence, immunohistochemistry, and near-infrared small animal optical imaging in vitro and in vivo. Moreover, by binding to HPV16 E6 protein, ZHPV16E61235 blocked E6-mediated p53 degradation, which increased the expression of some key p53 target genes, including BAX, PUMA and p21, and thereby selectively reduced the viability and proliferation of HPV16-positive cells. Importantly, ZHPV16E61235 was applied in combination with HPV16 E7-binding affibody ZHPV16E7384 to simultaneously target the HPV16 E6/E7 oncoproteins, and this combination inhibited cell proliferation more potently than either modality alone. Mechanistic studies revealed that the synergistic antiproliferative activity depends primarily on the induction of cell apoptosis and senescence but not cell cycle arrest. Our findings provide strong evidence that three novel HPV16 E6-binding affibody molecules could form a novel basis for the development of rational strategies for molecular imaging and targeted therapy in HPV16-positive preneoplastic and neoplastic lesions.

Inhibition of cervical cancer cell growth invitro and invivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6and E7oncogenes

Advances of RNAi in HPV16 E6/E7 of Cervical Cancer

Silencing of HPV11ET gene expression by different RNA interference technology

Selective Silencing of Viral Gene Expression in HPV6bE6-positive Cell Line Treated with Specific siRNA

Transcriptional Gene Silencing of HPV16 E6/E7 Induces Growth Inhibition Via Apoptosis in Vitro and in Vivo

Extended Effects of Human Papillomavirus 16 E6-specific Short Hairpin RNA on Cervical Carcinoma Cells.

Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7

Enhanced Immunotherapeutic Effect of Modified HPV16 E7-pulsed Dendritic Cell Vaccine by an Adeno-Shrna-socs1 Virus

Effects of Human Papillomavirus 16 E6-specific Short Hairpin RNA on Cervical Carcinoma Cell

Irreversible electroporation-mediated shRNA knockdown of the HPV18 E6 gene suppresses cervical cancer growth in vitro and in vivo

Mir-2861 Acts As a Tumor Suppressor Via Targeting EGFR/AKT2/CCND1 Pathway in Cervical Cancer Induced by Human Papillomavirus Virus 16 E6

Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells

Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo

In vitro study of HPV18-positive cervical cancer HeLa cells based on CRISPR/Cas13a system

HPV16 E6-Activated OCT4 Promotes Cervical Cancer Progression by Suppressing P53 Expression Via Co-Repressor NCOR1

Lentivirus-mediated Shrna Targeting XIAP and Survivin Inhibit SW1990 Pancreatic Cancer Cell Proliferation in Vitro and in Vivo.

Targeting X-linked Inhibitor of Apoptosis Protein Inhibits Pancreatic Cancer Cell Growth Through P-Akt Depletion.

Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells

RNA Interference Silences the Human Papillomavirus 6b/11 Early Gene E7 in Vitro and in Vivo.

The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer

Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes